Business UpdateAug 4, 2026, 08:34 AM
RenovoRx to Discuss Pancreatic Cancer, TAMP Platform at Webinar
AI Summary
RenovoRx, Inc. announced its participation in a JonesTrading webinar on August 13, 2026, to discuss its Trans-Arterial Micro-Perfusion (TAMP) platform and emerging clinical advances in pancreatic cancer. The webinar will cover the ongoing Phase III TIGeR-PaC clinical trial and the commercial progress of RenovoCath. The company reported RenovoCath sales of approximately $1.1 million in 2025 and a record $563,000 in Q1 2026, with full enrollment for TIGeR-PaC expected soon and data readout in mid to late 2027.
Key Highlights
- RenovoRx to participate in JonesTrading webinar on August 13, 2026, at 1:30 p.m. ET.
- Webinar to discuss the evolving pancreatic cancer landscape and RenovoRx's TAMP platform.
- Topics include the ongoing Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer.
- RenovoCath sales reached approximately $1.1 million in 2025.
- RenovoCath sales were a record $563,000 in the first quarter of 2026.
- Full enrollment for TIGeR-PaC trial is anticipated very soon, with data readout in mid to late 2027.
Price Impact
More from RNXT